Oral Composition Raising Oxidation-Reduction Potential to Inhibit Putrefaction

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing oral care products have not effectively addressed the common process of oral bacterial putrefaction, which leads to gingivitis, periodontitis, and oral malodor, by simultaneously lowering the oxidation-reduction potential (Eh) and failing to create an oral environment that inhibits these conditions.

Innovation Solution

An oral composition comprising at least one Eh-raising compound and at least one zinc compound, along with cetylpyridinium chloride (CPC), is used to inhibit the formation of sulfur-containing compounds, reduce oral malodor and gingivitis, and prevent the reduction of the oxidation-reduction potential in the oral cavity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If germicidal agents are used to treat gingivitis-periodontitis and oral malodor, then bacterial growth is inhibited, but the oxidation-reduction potential (Eh) is lowered and putrefaction is not effectively prevented

Engineering Contradiction:
Improveeffectiveness in preventing putrefactionVSAvoidoral malodor and gingivitis
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies parameter changes by modifying the oxidation-reduction potential (Eh) of the oral environment through zinc compounds and CPC. This shifts the chemical parameter of the oral cavity to a state that is inhospitable to putrefactive bacteria, thereby preventing the formation of malodorous compounds without relying solely on germicidal action.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates an inert oral environment by raising the Eh to levels that prevent anaerobic bacterial activity. This establishes a chemical atmosphere in the oral cavity that is non-conducive to putrefaction, effectively isolating the bacterial populations from conditions that enable harmful metabolic processes.

Inventive Principle:
Principle #39Inert atmosphere (Inert environment)

2Productivity

If oral care products focus on germicidal action, then bacterial killing is achieved, but the underlying putrefaction process is not addressed

Engineering Contradiction:
Improveoral health improvementVSAvoidputrefaction end-products
Core Design Contradiction:
ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful anaerobic environment into a beneficial aerobic environment by raising the Eh. This transforms the oral cavity from a state that promotes putrefaction to one that supports healthy bacterial populations, turning the previously harmful chemical conditions into a protective factor against disease.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If the oral environment maintains low Eh, then bacterial growth is controlled, but putrefaction continues and oral diseases persist

Engineering Contradiction:
Improveprevention of oral diseasesVSAvoidsulfur-containing compounds
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent fundamentally changes the Eh parameter of the oral environment to prevent the formation of sulfur-containing compounds. By maintaining a high Eh through zinc and CPC, the chemical conditions no longer support the metabolic pathways that produce these harmful putrefaction end-products.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentUS12318463B2Compositions and methods for treating canker sores
Publication Date: 2025.06.03 THE RES FOUNDATION FOR THE STATE UNIV OF NEW YORK
  • US12318463B2 patent drawing
  • US12318463B2 patent drawing
  • US12318463B2 patent drawing

AI summary

Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one Eh-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier.